Invenra and Catalent Collaborate to Accelerate Cancer Therapeutics Development

• Invenra has entered a strategic collaboration with Catalent to co-discover novel bispecific antibody-drug conjugates.

Invenra Inc., a bispecific antibody technology, has announced a strategic collaboration with Catalent to harness the combined expertise and proprietary technologies of both companies to co-discover novel bispecific antibody-drug conjugates.

This partnership is expected to leverage Invenra’s bispecific antibody technology and Catalent’s drug development solutions to create innovative treatments for cancer.

Dr. Roland Green, CEO of Invenra, expressed his excitement about the collaboration. He said, “We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary. We believe that the combination of Invenra’s B-Body bispecific antibody platform with Catalent’s SMARTag ADC expertise has the potential to unlock synergies and accelerate the development of next-generation cancer therapeutics.”